Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | RAMP3 | O60896 | 4/20 | 0.47 |
| ▸ | CALCR | P30988 | 4/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433176 | 0.91 | CAPN1 (0.52) | CAPN1RAMP3CALCRAPLNRCTSB | |
| SCHEMBL31433275 | 0.91 | CAPN1 (0.52) | CAPN1RAMP3CALCRAPLNRCTSB | |
| SCHEMBL31433337 | 0.87 | RAMP3 (0.55) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL29421104 | 0.87 | RAMP3 (0.49) | CAPN1RAMP3CALCRAPLNRPLK1 | |
| SCHEMBL29421085 | 0.87 | RAMP3 (0.49) | CAPN1RAMP3CALCRAPLNRPLK1 | |
| SCHEMBL31433316 | 0.87 | CAPN1 (0.61) | CAPN1APLNRCTSB | |
| SCHEMBL29611971 | 0.87 | CAPN1 (0.54) | CAPN1MAPK8MAPK9MAPK10RAMP3 | |
| SCHEMBL31433339 | 0.86 | MAPK8 (0.51) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL31433220 | 0.85 | RAMP3 (0.52) | MAPK8MAPK9MAPK10RAMP3CALCR | |
| SCHEMBL31433313 | 0.85 | MAPK8 (0.55) | MAPK8MAPK9MAPK10RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | CAPN1 3160/4885MAPK8 4358/4885MAPK9 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.